Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Annual versus semi-annual ocrelizumab dosing after 2 years in active multiple sclerosis
2023-505420-62-00Phase 3Authorised
- Sponsor
- Adolphe de Rothschild Foundation Hospital
- Start
- Jul 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of ocrelizumab in multiple sclerosis (MS) and secondary-progressive multiple sclerosis (SPMS) (2 arms), sponsored by Adolphe de Rothschild Foundation Hospital. Primary endpoint: No new or enlarged T2 lesions at 24 months. Planned start Jul 2023; status: authorised.
02
Drugs
ocrelizumab
03
Conditions
multiple sclerosis (MS)secondary-progressive multiple sclerosis (SPMS)
Beyond the preview
Go deeper on 2023-505420-62-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505420-62-00.